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Abstract
Background: Efﬁ  cacy of thrombolysis in acute ischemic stroke is strongly related to physician’s ability to make an accurate 
diagnosis and to intervene within 3–6 h after event onset. In this context, the discovery and validation of very early blood 
markers have recently become an urgent, yet unmet, goal of stroke research. Ubiquitin fusion degradation protein 1 is in-
creased in human postmortem CSF, a model of global brain insult, suggesting that its measurement in blood may prove 
useful as a biomarker of stroke.  
Methods: Enzyme-linked immunosorbent assay (ELISA) was used to measure UFD1 in plasma and sera in three indepen-
dent cohorts, European (Swiss and Spanish) and North-American retrospective analysis encompassing a total of 123 con-
secutive stroke and 90 control subjects. 
Results: Highly signiﬁ  cant increase of ubiquitin fusion degradation protein 1 (UFD1) was found in Swiss stroke patients 
with 71% sensitivity (95% CI, 52–85.8%), and 90% speciﬁ  city (95% CI, 74.2–98%) (N = 31, p < 0.0001). Signiﬁ  cantly 
elevated concentration of this marker was then validated in Spanish (N = 39, p < 0.0001, 95% sensitivity (95% CI, 82.7–
99.4%)), 76% speciﬁ  city (95% CI, 56.5–89.7%)) and North-American stroke patients (N = 53, 62% sensitivity (95% CI, 
47.9–75.2%), 90% speciﬁ  city (95% CI, 73.5–97.9%), p < 0.0001). Its concentration was increased within 3 h of stroke 
onset, on both the Swiss (p < 0.0001) and Spanish (p = 0.0004) cohorts. 
Conclusions: UFD1 emerges as a reliable plasma biomarker for the early diagnosis of stroke, and in the future, might be 
used in conjunction with clinical assessments, neuroimaging and other blood markers. 
Abbreviations: AUC: area under curve; BBB: blood–brain barrier; CO: cut-off; CSF: cerebrospinal ﬂ  uid; CT:  computer-
ized tomography; H-FABP: heart-fatty acid binding protein; MMP9: matrix metalloproteinase 9; MRI: magnetic resonance 
imaging; NDKA: nucleotide diphosphate kinase A; OR: odds ratio; RFU: relative ﬂ  uorescence units; ROC: receiver oper-
ating characteristic; rtPA: recombinant tissue plasminogen activator; SE: sensitivity; SP: speciﬁ  city; TIA: transient ischemic 
attack; UFD1: ubiquitin fusion degradation protein 1
Keywords: Diagnosis, Plasma Markers, Stroke, UFD1, Brain Damage.
Introduction
While stroke remains a leading cause of death and disability in industrialized countries, it has been 
demonstrated that a rapid assessment and early therapeutic intervention may improve the management 
and the long-term prognosis of stroke patients (Khaja and Grotta, 2007). At present, a diagnosis of 
stroke relies on physician’s neurological examination and neuroimaging techniques such as brain CT 
scan and/or MRI (Chalela et al. 2007). CT scan succeeds at detecting hemorrhagic stroke but usually 
fails at demonstrating ischemic lesions in their early phase. MRI can detect aspects of stroke within a 
few hours, but such sophisticated and expensive tools are available only in specialized hospitals. Rapid Biomarker Insights 2007: 2 156
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diagnosis and management of stroke remains a 
challenge as it suffers from a lack of reliable 
biological markers. An early diagnostic blood 
marker of stroke is expected to allow more rapid 
and appropriate therapeutic interventions and may 
possibly reduce the extent of tissue damage, 
disability and risk of death. Indeed, an efﬁ  cient 
thrombolytic treatment can only be considered 
within the crucial ﬁ  rst 3–6 h of the onset of symp-
toms (Albers and Olivot, 2007). Over the past few 
years, a number of blood markers including tau 
(Zemlan et al. 1999; Hesse et al. 2001; Bitsch et al. 
2002), neuron specific enolase (NSE), B-type 
neurotrophic growth factor (B-NGF) (Persson et al. 
1987; Cunningham et al. 1991; Zimmermann-Ivol 
et al. 2004), astroglial protein S-100b (Persson 
et al. 1987; Reynolds et al. 2003; Lynch et al. 
2004), glial fibrillary acidic protein (GFAP) 
(Herrmann et al. 2000), C-reactive protein (CRP) 
(Rost et al. 2001; Silvestri et al. 2004; Di Napoli 
et al. 2001; Intiso et al. 2004; Smith et al. 2004; 
Pedersen et al. 2004), matrix metalloproteinase 
(MMP9) (Lynch et al. 2004; Montaner et al. 2001; 
Reynolds et al. 2003), vascular and intracellular 
cell adhesion molecules (VCAM or ICAM) (Lynch 
et al. 2004; Pedersen et al. 2004), tumor necrosis 
factor-α (TNF-α) and interleukins (IL-1, IL-6 and 
IL-8) (Pedersen et al. 2004; Intiso et al. 2004; 
Silvestri et al. 2004; Smith et al. 2004) have raised 
interest in the diagnosis and prognosis of stroke. 
Nevertheless, limitations for these markers are that 
(i) they displayed either low sensitivity or speci-
ﬁ  city in differentiating stroke and control patients, 
(ii) they were tested in limited samples with similar 
genetic background, ranging from a few patients 
to 223 for the most extensive study by Reynolds 
et al. 2003 or (iii) they are released in blood rela-
tively late after stroke onset.
The main objective of the present study was to 
evaluate ubiquitin fusion degradation protein 1 
(UFD1) as a new blood marker that could help in 
the early diagnosis of stroke patients. We have 
recently explored postmortem cerebrospinal ﬂ  uid 
(CSF) as a model of massive brain insult (Lescuyer 
et al. 2004). CSF is an ideal ﬂ  uid to use in the 
search of biomarkers of brain damaged-associated 
disorders. Owing to the close proximity of CSF to 
the brain, changes that are detected in the protein 
composition of CSF often reﬂ  ect changes that 
currently occurred or have previously occurred in 
the brain. For example, heart-fatty acid binding 
protein (H-FABP) was initially found over-
expressed in postmortem compared to antemortem 
CSF and was validated as a potential biomarker of 
Creutzfeld–Jakob disease (Guillaume et al. 2003) 
and stroke (Zimmermann-Ivol et al. 2004). More 
recently, RNA binding protein regulatory subunit 
(PARK7) and nucleotide diphosphate kinase A 
(NDKA), also identiﬁ  ed in postmortem CSF were 
validated as early plasmatic markers of stroke 
(Allard et al. 2005). UFD1 was similarly found 
over-expressed in postmortem compared to ante-
mortem CSF. Altogether, the above-mentioned data 
suggested that UFD1 could also be released in the 
blood of patients affected by a brain injury. Here, 
we report the evaluation of UFD1 levels in three 
independent cohorts, demonstrating its utility as a 
blood biomarker of stroke. 
Materials and Methods
Blood samples for UFD1 validation
Plasma and sera samples were obtained from two 
European (Swiss and Spanish) and one North-
American cohort of patients, which were used for 
the assessment of UFD1 level. 
The local institutional ethical committee board 
of each centre approved the clinical protocol. The 
diagnosis of stroke was established by a trained 
neurologist and was based on the sudden appear-
ance of a focal neurological deﬁ  cit and the subse-
quent delineation of a lesion consistent with the 
symptoms on brain CT or MRI images, with the 
exception of transient ischemic attacks (TIAs) 
where a visible lesion was not required for diag-
nosis. After centrifugation at 1500 g for 15 min at 
4 °C, heparin-plasma samples were aliquoted and 
stored at –80 °C until analysis. For the sera, blood 
samples were allowed to clot for 15 min at room 
temperature and were then centrifuged for 5 min 
at 1500 g at 4 °C. Samples were aliquoted and 
stored at –80 °C until analysis. Analyses were 
performed on frozen samples.
Swiss cohort
Sixty-six consecutive Swiss stroke and control 
patients admitted to the Geneva University Hospital 
emergency unit were enrolled in this study between 
August 1996 and January 1997 (Table 1). Two 
stroke patients were excluded, as they ﬁ  nally did 
not have a stroke. Two control patients were also 
excluded from the study because of sustaining a Biomarker Insights 2007: 2 157
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stroke shortly after the blood withdrawal. Of the 
62 consecutive patients enrolled, 31 were diag-
nosed with non-neurological conditions and clas-
siﬁ  ed as control samples (21 men and 10 women, 
average age of 70.26 years, range 28–91 years) and 
31 were diagnosed with stroke (23 men and 8 
women, average age of 71.81 years, range 25–92 
years) including 28 ischemic (among them 6 TIAs, 
22 established) and 3 intra-cerebral hemorrhagic 
strokes. The control group included patients with 
various medical or surgical conditions, including 
cancer (n = 12) and gastro-intestinal disorders. A 
few of them suffered from chronic neurological 
conditions as secondary diagnosis, including 
meningioma (n = 1) and dementia (n = 3). None 
of them had a past or recent history of cerebrovas-
cular event. For each patient, a blood sample was 
collected at the time of admission in dry heparin-
containing tubes. For the patients of the stroke 
group, the average time interval between the neuro-
logical event and the ﬁ  rst blood draw was 20.11 h 
(range 30 min to 5 days).
Spanish cohort
Twenty-nine control and 39 stroke patients were 
enrolled in this study (Table 1). Tests were 
performed on sera samples. The stroke subgroup 
included 10 hemorrhagic and 29 ischemic patients. 
The ischemic population was divided into (i) 
cardioembolic among them partial (n = 5) and total 
(n = 4) anterior circulation infarct, (ii) atherothrom-
botic among them partial (n = 5) and total (n = 5) 
anterior circulation infarct and (iii) lacunar infarct 
Table 1. Demographic characteristics of Swiss, Spanish and North-American samples. 
 Stroke  Control
Swiss cohort
n  31 31
Age mean ± SD (min–max)  71.8 ± 15.6(25–92)  71.3 ± 16.0(28–91)
Female n (%)/Male n (%)  8(25.8)/23(74.2)  10(32.3)/21(67.8)
Time after onset of symptoms (h)  20.1 ± 30.1(0.5–120)  –
Mean ± SD (min–max)  3.9(2.1–48)
Median (25–75 percentiles)
Hemorrhagic n (%)  3(9.7)  –
TIA n (%)  6(19.3)  –
Ischemic n (%)  22(71.0)  –
Spanish cohort
n  39 29
Age mean ± SD (min–max)  70.2 ± 12.1(44–95)  69.3 ± 9.5(54–87)
Female n (%)/Male n (%)  17(43.6)/22(56.4)  14(48.3)/15(51.7)
Time onset of symptoms (h)
Mean ± SD (min–max)  10.03 ± 29.96 (0.5–150)  –
Median (25–75 percentiles)  3.05(1.92–7.27)
Hemorrhagic n (%)  10(25.6)  –
Ischemic n (%)  29(74.4)  –
Cardioembolic PACI n (%)  5(12.8)  –
Cardioembolic TACI n (%)  4(10.4) 
Lacunar n (%)  5(12.8) 
Atherothrombotic PACI n (%)  5(12.8)  –
Atherothrombotic TACI n (%)  5(12.8)  –
TIA n (%)  5(12.8)  –
North-American cohort
n 53  30
Hemorrhagic n (%)  6(11.3)  –
TIA n (%)  23(43.4)  –
Ischemic n (%)  24(45.3)  –
SD, standard deviation; PACI, partial anterior circulation infarct; TACI, total anterior circulation infarct; TIA, transient ischemic attack.Biomarker Insights 2007: 2 158
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(n = 5) and TIA (n = 5). The 39 stroke patients were 
recruited within 24 h after onset of symptoms, and 
exact time was obtained for 18 patients. The 
average time interval between the neurological 
event and the ﬁ  rst blood draw for these patients 
was 10.0 h (range 30 min to 6.25 days).
North-american cohort
A North-American cohort was included and studied 
as described by Reynolds et al. Brieﬂ  y, it was 
composed of 30 control and 53 stroke patients 
(including 6 hemorrhagic, 23 TIAs and 24 estab-
lished ischemic strokes). Blood samples were 
collected within 24 h after the onset of symptoms 
(Table 1). 
Sandwich ELISA Immunoassay 
procedure
The ELISA was performed using 96-well Reacti-
Bind
TM NeutrAvidin
TM coated Black Plates (Pierce, 
Rockford, IL). Plates were ﬁ  rst rinsed in borate 
buffer saline pH 8.4 (BBS) (100 mM H3BO3, 
25 mM Na2B4O7 (Sigma, St. Louis, MO, USA) 
75 mM NaCl (Merck, Darmastadt, Germany)) on 
a NOVAPATH
TM washer (Bio-Rad, Hercules, CA). 
Then, 50 µL of UFD1 antibody-biotin conjugated 
(2 µg/mL) (Biosite, California, USA) prepared in 
the dilution buffer A at pH 7 (DB, Polyvinyl 
Alcohol, 80% hydrolyzed, MW 9000–10,000 
(Aldrich, Milwaukee, WI, USA), MOPS (Sigma), 
NaCl, MgCl2 (Sigma), ZnCl2 (Aldrich), pH 6.90, 
BSA 30% Solution, Manufacturing Grade (Sero-
logical Proteins Inc., Kankakee, IL)), were added 
and incubated for 1 h at 37 °C. Plates were then 
washed three times in BBS in the plate washer. The 
recombinant protein UFD1 (Biosite, California, 
USA) was diluted at 100 ng/mL in the dilution 
buffer A. Plasma and sera samples were diluted 
twice in the dilution buffer A. Fifty microliter of 
antigen was then added and incubated for 1 h at 
37 °C. After washing, 50 µL of alkaline phospha-
tase conjugated UFD1 antibodies (Biosite, Cali-
fornia, USA) was added at the appropriate dilution 
in the dilution buffer A and incubated for 1 h at 
37 °C. The 96-well plate was then washed three 
times with BBS in the plate washer and 50 µL of 
ﬂ  uorescence Attophos
® AP Fluorescent substrate 
(Promega, Madison, WI) was added. Plates were 
read immediately on a SpectraMax GEMINI-XS 
(Molecular Devices Corporation, Sunnyvale, CA, 
USA) ﬂ  uorometer microtiter plate reader using the 
endpoint mode relative ﬂ  uorescence units (RFU) 
(λexcitation = 444 nm and λemission = 555 nm). The 
European cohorts were tested in Geneva (CH) on 
96-well microtiter plates and the North-American 
cohort in San Diego (CA) on a fully automated 
TECAN platform using 384-well microtiter plates. 
Each sample was assayed in duplicate and distrib-
uted randomly on the plate. The intra- and inter-run 
coefﬁ  cient of variations was always under 10%. 
Calibration curves were performed in the same 
plate using the recombinant protein. The UFD1 
recombinant protein was diluted to concentrations 
of 100, 50, 25, 12.5, 6.25, 3.125, 1.56 and 0 µg/L 
in the dilution buffer in Geneva and in control 
plasma in San Diego. A calibration curve was 
performed using a linear regression in the linear 
range of the curve (1.56–50 µg/L). Protein levels 
were initially expressed in relative ﬂ  uorescence 
units (RFU) and the concentrations were calculated 
via the calibration curve.
Statistical analysis
Statistical analyses were performed using 
GraphPad Prism
® software version 4.0 (GraphPad 
Software Inc., San Diego, C.A, U.S.A.) and graphs 
were produced with Aabel 1.5.8 software (Gigawiz 
Ltd. Co.). Notched box and whisker charts were 
drawn, that shows 10th, 25th, 50th, 75th and 90th 
percentiles and outliers. The diamond-shape indi-
cates the mean. The notches in the boxes corre-
spond to the median and its conﬁ  dence interval. 
Boxes whose notches do not overlap indicate that 
the medians of the two groups differ at the 5% 
signiﬁ  cance level. To assess the performance of 
protein levels to discriminate between stroke and 
control samples, a non-parametric Mann–Whitney 
test was performed. For comparing sub-samples 
according to the time interval between blood 
samples and onset of symptoms, a one-way 
Kruskal–Wallis ANOVA followed by Dunn’s 
multiple comparison tests was carried out. Receiver 
operating characteristic (ROC) curve analyses were 
performed and cut-off (CO) values were obtained 
from the curves. When possible, optimal threshold 
value was chosen at speciﬁ  city ideally above 90%, 
as this parameter is the most clinically relevant to 
rule-in ischemic stroke patients. Odds ratios (OR) 
were also calculated for each sample. A Fisher’s 
exact test and a Mann–Whitney test were used to 
check, respectively, if sex and age did not differ Biomarker Insights 2007: 2 159
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signiﬁ  cantly between stroke and controls. Compar-
ison of ROC curves was performed using MedCalc 
version 8.2.
Results
Ubiquitin fusion degradation protein 1 (UFD1, 
Swiss-Prot Accession No. Q92890 of 343 AA, 
38725 Da and theoretical pI 5.96) was measured 
and validated in three independent cohorts. 
A Swiss cohort comprising 62 consecutive 
patients and described in Table 1, was investigated. 
Stroke and control patients did not statistically 
differ with respect to age (p = 0.725, Mann–
Whitney test) and sex (p = 0.78, Fisher’s exact 
test). UFD1 was evaluated for its ability to differ-
entiate stroke and control patients, irrespective of 
stroke type, lesion size or location. Figure 1A 
shows a highly signiﬁ  cant increase of UFD1 in the 
stroke samples compared to the controls (Mann–
Whitney test, p < 0.0001). The best cut-off value 
that differentiated control and stroke patients was 
calculated using a ROC curve (Fig. 1B). Table 2 
indicates that a diagnosis of stroke may be estab-
lished with 71.0% sensitivity and 90.3% speciﬁ  city 
for a UFD1 cut-off of at 3.76 µg/L (AUC 0.90, 
95% CI 0.82–0.98, p < 0.0001). This corresponded 
to 9 false negative and 3 false positive results out 
of 31 (OR 22.8, 95% CI 5.5–94.5; Fischer’s exact 
test, p < 0.0001). Interestingly, the control cohort 
included four patients suffering from various 
neurological conditions, including sleep apnea 
syndrome and meningioma (n = 1) and dementia 
(one with ischemic colitis and two with hip frac-
ture) (n = 3). None of these patients showed posi-
tive results with the biomarker, strengthening its 
specificity. The plasma level of UFD1 was 
evaluated as a function of the time interval 
between blood collection and stroke onset. The 
ischemic stroke samples (established and tran-
sient) were divided into patients with interval 
below 3 h (n = 11) and above 3 h (n = 17). 
Figure 2 clearly shows a significant increase of 
the protein level within the first 3 h after stroke 
onset compared to the control sample (p < 0.0001, 
Kruskal–Wallis test with post hoc Dunn’s 
multiple comparisons).
A Spanish cohort comprising 29 control and 39 
stroke patients and described in Table 1 conﬁ  rmed 
these results. Stroke and control patients did not 
statistically differ with respect to age (p = 0.5934), 
Mann–Whitney test) and sex (p = 0.807, Fisher’s 
exact test). A signiﬁ  cant increase of UFD1 was 
observed among stroke patients (p < 0.0001, 
Mann–Whitney test) (Fig. 3A). It was possible to 
diagnose stroke with 94.9% sensitivity and 75.9% 
speciﬁ  city with a cut-off at 2.26 µg/L (AUC 0.84, 
95% CI 0.73–0.95, p < 0.0001) (Fig. 3B, Table 2). 
This corresponded to 2 false negative out of 39 
stroke patients and 7 false positive out of 29 control 
subjects (OR 58.1, 95%CI 11.1 305.2, Fischer’s 
exact test, p < 0.0001). No difference between 
stroke subtypes (hemorrhagic, ischemic and TIA) 
was observed (p > 0.05, Kruskal–Wallis test with 
post hoc Dunn’s multiple comparisons). As for the 
Swiss cohort, the ischemic stroke Spanish popula-
tion (established and transient) was divided into 
patients with time onset of symptoms below 3 h 
(n = 11) and above 3 h (n = 7). About 10 hemor-
rhagic and 11 ischemic patients with unclear time 
onset of symptoms but below 24 h were removed 
from the study. Figure 4 clearly shows a signiﬁ  cant 
Figure 1. (A) UFD1 concentrations in stroke vs. control Swiss patients. Notched box and whisker charts show 10th, 25th, 50th, 75th and 
90th percentiles and outliers. The diamond-shape indicates the mean. (B) UFD1 ROC curve. The arrow indicates the cut-off that gives the 
best sensitivity and speciﬁ  city described in Table 2.Biomarker Insights 2007: 2 160
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Figure 2. UFD1 concentrations as a function of time after the onset 
of the symptoms (Ischemic and TIA patients) for the Swiss population. 
Notched box and whisker charts show 10th, 25th, 50th, 75th and 
90th percentiles and outliers. The diamond-shape indicates the 
mean.
increase of the protein within the ﬁ  rst 3 h after 
stroke onset compared to the control population 
(p = 0.0004, Kruskal–Wallis test with post hoc 
Dunn’s multiple comparisons).
UFD1 was also tested in a North-American 
sample described in Table 1. Box plots display a 
signiﬁ  cant increase of UFD1 in stroke patients 
compared to controls (Fig. 5A). Using ROC curves 
(Fig. 5B), we determined that it was possible to 
diagnose stroke (hemorrhagic plus TIA plus isch-
emic) with 62.3% sensitivity and 90.0% speciﬁ  city 
with a cut-off at 0.45 µg/L (Table 2) (AUC 0.85, 
95% CI 0.76–0.93, p < 0.0001). This corresponded 
to 3 false positive out of 30 controls and 20 false 
negative out of 53 stroke patients (OR 10.7, 95% 
CI 3.3–35.3, Fischer’s exact test, p < 0.0001). Each 
subtype of stroke (hemorrhagic, TIA or ischemic) 
showed a signiﬁ  cant increase compared to controls 
(p < 0.01, Kruskal–Wallis test, post hoc Dunn’s 
multiple comparisons, data not shown). No signif-
icant difference between stroke subtypes was 
observed.
Finally, we compared the performance of 
UFD1 with PARK7 and NDKA (two biomarkers 
previously validated in our laboratory) in the 
Swiss and North-American cohorts. Table 2 
shows that UFD1 displays similar results as 
PARK7 and NDKA, in terms of sensitivity and 
specificity. In order to determine the best marker 
among the three tested, we compared areas under 
ROC curves (Table 2). Pairwise comparison of the 
six ROC curves (UFD1, PARK7 and NDKA in the 
Swiss and North-American studies) (Table 3) 
shows no signiﬁ  cant differences (p > 0.05) except 
between UFD1 and PARK7 in the North-American 
studies (p = 0.005). However, this result was not 
confirmed within the Swiss cohort (p = 0.961).
Discussion
The present small multi-centric study tested the 
hypothesis that UFD1 is increased in plasma and 
sera samples of stroke patients. This was demon-
strated across three independent cohorts encom-
passing 90 control and 123 stroke patients with 
Table 2. Comparison of the performance of the three early diagnostic blood markers of stroke UFD1, PARK7 
and NDKA. 
 Ctrl  n  Stroke n  AUC Cut-off  SE%  SP%
  FP  FN  95% CI  (µg/L)  95% CI  95% CI
UFD1-Spanish 29  39  0.84(0.73–0.95)  2.26  94.9(82.–  99.4%)  75.9(56.5–89.7%)
 7  2
UFD1-Swiss 31 31  0.90(0.82–0.98)  3.76  71.0(52.0–85.8%)  90.3(74.2–98.0%)
 3  9
UFD1-USA   30  53  0.85(0.76–0.93)  0.45  62.3(47.9–75.2%)  90.0(73.5–97.9%)
 3  20 
PARK7-Swiss 35  35  0.88  (0.80–0.97) 9.33  91.4(76.9–98.2%)  80.0(63.1–91.6%)
 7  3
PARK7-USA 30 53  0.970.94–1.00) 1.55  84.9(72.4–93.2%)  96.7(82.8–99.9%)
 1  8
NDKA-Swiss 31  31  0.94(0.86–1.00)  2  90.3(74.2–98.0%)  90.3(74.2–98.0%)
 3  3
NDKA-USA 30  51  0.94(0.89–0.99)  2.55 72.6(58.3–84.1%)  96.7(82.8–99.9%)
 1  14
Ctrl, control; FN, false negative; FP, false positive; SE, sensitivity; SP, speciﬁ  city; CI, conﬁ  dence interval.Biomarker Insights 2007: 2 161
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different genetic background (Swiss, Spanish and 
North-American). Assays were performed in two 
different places, Switzerland and the United States. 
Results in terms of sensitivity and speciﬁ  city ranged 
from 62.3–94.9% for sensitivity and 75.9–90.3% 
for specificity. The comparison of UFD1 with 
PARK7 and NDKA within the Swiss and American 
cohorts shows that the three proteins display similar 
sensitivities and speciﬁ  cities. Comparison of the 
AUC did not allowed to determine the best marker 
among UFD1, PARK7 and NDKA within Swiss and 
North-American studies. 
Using the Swiss and Spanish cohorts, we have 
demonstrated that it was possible to diagnose 
ischemic stroke patients early after a stroke event, 
i.e. within the ﬁ  rst 3 h when a thrombolytic treat-
ment can still be considered. In this context, it is 
hypothesized that UFD1 could be used as a follow-
up marker for treated ischemic stroke patients. In 
addition, four controls with neurological disorders 
(dementia and meningioma) appeared negative for 
UFD1, suggesting speciﬁ  city of the test regarding 
such disorders. Nevertheless, a large-scale study 
on stroke-mimic patients such as migraine, seizure 
or metabolic disorders should be performed. More-
over, 12 patients with high troponin I levels (acute 
myocardial infarction) did not showed signiﬁ  cant 
elevated concentration of UFD1 compared to 
controls (data not shown). This result reinforces 
specificity of UFD1 as a diagnosis marker of 
stroke, compared to other vascular diseases.
The identiﬁ  cation of UFD1 was based on its 
speciﬁ  c appearance in postmortem CSF presum-
ably as a result of global brain ischemia and 
necrosis following death. We believe this model 
may partly reproduce mechanisms underlying the 
ischemic cascade of events leading to stroke 
lesions. The protein content of CSF has been exam-
ined in detail and many proteomic analyses of 
normal CSF (Finehout et al. 2004; Maccarrone 
et al. 2004), CSF from aging subjects (Zhang et al. 
2005) or CSF from patients with neurological 
disorders such as multiple sclerosis (Hammack 
et al. 2004; Dumont et al. 2004), Frontotemporal 
dementias (Davidsson et al. 2002a; Folkesson 
Hansson et al. 2004) and Alzheimer’s disease 
Figure 3. (A) UFD1 concentrations in stroke vs. control Spanish patients. Notched box and whisker charts show 10th, 25th, 50th, 75th and 
90th percentiles and outliers. The diamond-shape indicates the mean. (B) UFD1 ROC curve. The arrow indicates the cut-off that gives the 
best sensitivity and speciﬁ  city described in Table 2.
Figure 4. UFD1 concentrations as a function of time after the onset 
of the symptoms (Ischemic and TIA patients) for the Spanish popu-
lation. Notched box and whisker charts show 10th, 25th, 50th, 75th 
and 90th percentiles and outliers. The diamond-shape indicates the 
mean.Biomarker Insights 2007: 2 162
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(Davidsson et al. 2002b) have been recently 
published. However, the current knowledge of the 
protein content of CSF is likely to be largely 
incomplete and many more proteins will be identi-
ﬁ  ed in this biological ﬂ  uid. It is therefore not 
surprising that Lescuyer and his co-workers only 
identiﬁ  ed UFDI in postmortem CSF. This biomarker 
exhibits particular features, which makes it an 
appropriate candidate for reﬂ  ecting aspects of 
ischemic brain injury. UFD1L gene encodes for the 
ubiquitin fusion degradation protein 1 (UFD1). 
UFD1 is highly expressed in adult heart, skeletal 
muscle and pancreas and to a lesser extend in 
placenta, lung, liver, kidney and brain. It was also 
found in fetal liver and kidney (Pizzuti et al. 1997). 
It is an essential component of the ubiquitin-depen-
dent proteolytic pathway, which degrades ubiquitin 
fusion proteins. Deletions on chromosome 22q11.2 
coding for UFD1L are associated with cardiac and 
craniofacial developmental defects that are charac-
teristic of the DiGeorge syndrome (DGS), the velo-
cardio-facial syndrome (VCFS) (Yamagishi et al. 
1999; Driscoll et al. 1992) and the Opitz G/BBB 
syndrome (McDonald-McGinn et al. 1995) all 
known under the term of CATCH22 syndrome. A 
high prevalence of psychiatric disorders was 
observed in such patients and some groups have 
reported an involvement of UFD1L gene polymor-
phism in schizophrenia (De Luca et al. 2001; Bassett 
and Chow, 1999). The exact function of UFD1 in 
the pathogenesis of stroke is still unknown, but 
recently, it has been proposed that the ubiquitin-
proteasome system contributes to neurodegenera-
tion, in particular in Parkinsons’disease (Ross and 
Pickart, 2004) and to cerebral ischemic injury. 
Indeed, proteasome inhibition appears as a potential 
treatment in stroke by reducing neuronal and astro-
cytic degeneration, cortical infarct volume, infarct 
neutrophil inﬁ  ltration and NF-kB immunoreactivity 
with an extension of the neuroprotective effect at 
least 6 h after ischemic insult (see Wojcik and Di 
Napoli, 2004).
Based on the known distribution and function 
of UFD1, several hypotheses can be proposed 
regarding the mechanisms by which UFD1 may 
gain access to and be over-expressed in the blood 
of stroke patients. However, leakage through a 
disrupted blood–brain barrier (BBB) appears to be 
a likely, direct and nearly immediate route for 
UFD1 to appear in the blood. 
In conclusion, UFD1 appears to be a reliable 
biomarker for the early diagnosis of ischemic 
stroke. As CT scan can exclude conditions such as 
tumor or hemorrhagic stroke, measurement of 
UFD1 plasma level could provide a powerful tool 
to rule-in ischemic stroke patients as a complement 
to clinical assessment and CT or MRI scan studies. 
Further investigations are currently underway to 
develop a 15-min lateral ﬂ  ow assay to evaluate 
prospectively UFD1 as a diagnostic marker of 
ischemic stroke and a follow-up biomarker in rtPA 
treated patients.
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